Finally, we strongly believe that PUM1 and RNase P as cfDNA markers in plasma could provide a valuable tool for BC screening in conjunction with mammograms to obtain an improved selection of patient candidates for biopsy or closer follow‐up. This evidence concerns the gene PUM1 and breast cancer.